Skip to main content
Premium Trial:

Request an Annual Quote

Oncocyte to Acquire Chronix Biomedical

NEW YORK – Oncocyte said Tuesday that it has agreed to acquire German diagnostics firm Chronix Biomedical.

Under the agreement, which supersedes a previously announced collaboration between the companies, Oncocyte will acquire Chronix's cancer immunotherapy monitoring test, TheraSure-CNI Monitor, as well as the intellectual property for its organ transplant monitoring technology.

Chronix's CNI test quantitatively measures the level of copy number variation present in a cancer patient's blood. The company has shown in previous data that changes in CNI over time correspond to response or lack thereof to cancer immunotherapy.

The terms of the acquisition include Oncocyte delivering $2.675 million in cash and $1.5 million of its common stock (or approximately 295,000 shares) at closing of the transaction. The company also will assume liabilities not to exceed $5.5 million. The agreement also provides for Oncocyte to pay a revenue share on the net collected revenues for certain tests and services for specific periods and to pay a combination of cash or common stock of up to $14 million if certain milestones are achieved.

The merger is subject to approval of the transaction by Chronix shareholders and is expected to be completed by April 30, 2021. At that time, Chronix’s development and business team will become part of Oncocyte's R&D department, but will maintain lab operations in Germany, where it will continue development and work toward commercial launch of the two monitoring tests. This EU-based team will also lead Oncocyte’s commercial efforts for its DetermaRx and DetermaIO tests in the region.

Irvine, California-based Oncocyte said it expects to launch TheraSure-CNI Monitor for research use and pharma trials in the second half of 2021 and intends to accelerate further validation of the assay to support clinical use.

"We believe that acquiring Chronix … provides us with a strong patent portfolio that can serve as the basis for our blood-based therapy monitoring and recurrence monitoring programs, and ultimately create significant value for Oncocyte. The acquisition also establishes a footprint in the EU for our Company and access to an incredibly talented team with years of development experience in blood-based testing for cancer therapy and transplant rejection," Oncocyte CEO Ron Andrews said in a statement.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.